



Australian Government

Department of Health and Aged Care

National Immunisation Program (NIP) Business Rules

Digital Australian Immunisation
Handbook System (DAIHS)

National Immunisation Catch-Up
Calculator (NICC)

Cohort: Children and Adolescents
Under 20 Years (v4.2)

Contents

1	Purpose	6
2	References	6
3	Document Details	6
3.1	Version Control	6
3.2	Document Location	6
4	General Provisions	7
4.1	NICC Considerations/Exceptions	7
4.2	Infanrix hexa Rule	7
4.3	Medical risk conditions Rule	8
4.4	Additional funding rules for vaccines	8
4.5	Entering historical doses	8
4.6	Entering overseas doses	8
5	Diphtheria-tetanus-acellular pertussis (DTPa)	9
5.1	Recommended schedule	9
5.1.1	All children and adolescents	9
5.1.2	Aboriginal and Torres Strait Islander children and adolescents	9
5.1.3	People with specified medical conditions	9
5.2	Catch up dose parameters	10
5.2.1	All children and adolescents	10
5.2.2	People with specified medical conditions	11
5.3	NIP funding	12
6	Haemophilus Influenzae Type b (Hib) PRP-T	13
6.1	Recommended schedule	13
6.1.1	All children and adolescents	13
6.1.2	Aboriginal and Torres Strait Islander children and adolescents	13
6.1.3	People with specified medical conditions	13
6.2	Catch up dose parameters	13
6.2.1	All children and adolescents	13
6.2.2	People with specified medical conditions	14
6.3	NIP funding	16
7	Hepatitis A	17
7.1	Recommended schedule	17
7.1.1	Non-Aboriginal and Torres Strait Islander children in all states and Aboriginal and Torres Strait Islander children in ACT, NSW, TAS & VIC	17
7.1.2	Aboriginal and Torres Strait Islander children in NT, QLD, SA or WA	17
7.1.3	People with specified medical conditions in all states and territories	17
7.2	Catch up dose parameters	17
7.2.1	Aboriginal and Torres Strait Islander children in NT, QLD, SA or WA	17
7.2.2	People with specified medical conditions in all states and territories	18
7.3	NIP funding	19

8	Hepatitis B	20
8.1	Recommended schedule.....	20
8.1.1	All children and adolescents.....	20
8.1.2	Aboriginal and Torres Strait Islander children and adolescents.....	20
8.1.3	People with specified medical conditions.....	20
8.2	Catch up dose parameters.....	21
8.2.1	All children and adolescents.....	21
8.2.2	People with specified medical conditions.....	22
8.3	NIP funding.....	23
9	Human Papillomavirus (HPV)	24
9.1	Recommended schedule.....	24
9.1.1	All adolescents.....	24
9.1.2	Aboriginal and Torres Strait Islander people.....	24
9.1.3	Adolescents with specified medical conditions.....	24
9.2	Catch up dose parameters.....	24
9.2.1	All adolescents.....	24
9.2.2	Adolescents with specified medical conditions.....	25
9.3	NIP funding.....	26
10	Inactivated poliomyelitis vaccine (IPV)	27
10.1	Recommended schedule.....	27
10.1.1	All children and adolescents.....	27
10.1.2	Aboriginal and Torres Strait Islander children and adolescents.....	27
10.1.3	People with specified medical conditions.....	27
10.2	Catch up dose parameters.....	27
10.2.1	All children and adolescents.....	27
10.2.2	People with specified medical conditions.....	28
10.3	NIP funding.....	29
11	Influenza	30
11.1	Recommended schedule.....	30
11.1.1	All people.....	30
11.1.2	Aboriginal and Torres Strait Islander people.....	30
11.1.3	People with specified medical conditions.....	30
11.2	Catch up dose parameters.....	30
11.2.1	All people.....	30
11.2.2	People with specified medical conditions.....	31
11.3	NIP funding.....	31
12	Measles-Mumps-Rubella (MMR)	32
12.1	Recommended schedule.....	32
12.1.1	All children and adolescents.....	32
12.1.2	Aboriginal and Torres Strait Islander children and adolescents.....	32
12.1.3	People with specified medical conditions.....	32
12.2	Catch up dose parameters.....	33
12.2.1	All children and adolescents.....	33
12.2.2	People with specified medical conditions.....	34
12.3	NIP funding.....	34

13	Meningococcal ACWY Conjugate (MenACWY)	35
13.1	Recommended schedule	35
13.1.1	All children and adolescents	35
13.1.2	Aboriginal and Torres Strait Islander children	35
13.1.3	People with specified medical conditions	35
13.2	Catch up dose parameters	36
13.2.1	All children and adolescents	36
13.2.2	People with specified medical conditions	38
13.3	NIP funding	41
14	Meningococcal B (MenB)	42
14.1	Recommended schedule	42
14.1.1	All children and adolescents	42
14.1.2	Aboriginal and Torres Strait Islander children	42
14.1.3	People with specified medical conditions	42
14.2	Catch up dose parameters	43
14.2.1	All children and adolescents	43
14.2.2	People with specified medical conditions	44
14.3	NIP funding	47
15	Pneumococcal conjugate	48
15.1	Recommended schedule	48
15.1.1	Non-Aboriginal and Torres Strait Islander children in all states and Aboriginal and Torres Strait Islander children and adolescents in ACT, NSW, TAS & VIC	48
15.1.2	Aboriginal and Torres Strait Islander children and adolescents in NT, QLD, SA or WA ..	48
15.1.3	People with specified medical conditions	48
15.2	Catch up dose parameters	50
15.2.1	Non-Aboriginal and Torres Strait Islander children in all states and Aboriginal and Torres Strait Islander children and adolescents in ACT, NSW, TAS & VIC	50
15.2.2	Aboriginal and Torres Strait Islander children and adolescents in NT, QLD, SA or WA ..	51
15.2.3	People with specified medical conditions	53
15.3	NIP funding	54
16	Pneumococcal polysaccharide	56
16.1	Recommended schedule	56
16.1.1	Non-Aboriginal and Torres Strait Islander children in all states and Aboriginal and Torres Strait Islander children in ACT, NSW, TAS & VIC	56
16.1.2	Aboriginal and Torres Strait Islander children and adolescents in NT, QLD, SA or WA ..	56
16.1.3	People with specified medical conditions	56
16.2	Catch up dose parameters	58
16.2.1	Aboriginal and Torres Strait Islander children and adolescents in NT, QLD, SA or WA ..	58
16.2.2	People with specified medical conditions	58
16.3	NIP funding	59
17	Rotavirus	60
17.1	Recommended schedule	60
17.1.1	All children	60
17.1.2	Aboriginal and Torres Strait Islander children	60
17.1.3	Children with specified medical conditions	60
17.1.4	Catch up dose parameters	60

18 Varicella..... 61

- 18.1 Recommended schedule..... 61
 - 18.1.1 All children and adolescents..... 61
 - 18.1.2 Aboriginal and Torres Strait Islander children and adolescents 61
 - 18.1.3 People with specified medical conditions 61
- 18.2 Catch up dose parameters 61
 - 18.2.1 All children and adolescents..... 61
 - 18.2.2 People with specified medical conditions 62
- 18.3 NIP funding..... 63

1 Purpose

This document describes the agreed business rules stipulated for the Australian Immunisation Handbook (AIH) National Immunisation Catch-up Calculator for the '**Children and Adolescents Under 20 Years of Age**' cohort.

These rules are the basis for the software code development for the online calculator available on the official Australian Immunisation Handbook (AIH) [website](#).

2 References

The NICC Cohort rules for each antigen listed in this document have been developed using the following reference sources:

- Online Australian Immunisation Handbook (AIH)
- National Immunisation Program (NIP) Schedule for each state and territory.
- Compromised Vaccine Guidelines for Jurisdictional Immunisation Coordinators, Australian Technical Advisory Group on Immunisation (ATAGI), November 2012
- [The Australian Immunisation Register \(AIR\) National Due and Overdue Rules](#)
- National Centre for Immunisation Research and Surveillance (NCIRS)

3 Document Details

3.1 Version Control

Version	Date	Details
1.0	1 March 2020	Initial rules extracted from SA Health document
1.1	30 June 2020	ATAGI July 2020 Updates
3.61	June 2022	Refinements to business rules to better cater to children under 10 years with multiple at-risk conditions.
4	June 2023	Expanded business rules to include catch-up recommendations for all infants, children, and adolescents under the age of 20.
4.1	April 2024	Minor refinements to the business rules for splenectomy (Men ACWY & Men B) and heart transplant (Men B).
4.2	June 2024	Minor refinements to business rules for DTPa, Men ACWY, and MenB to improve clarity.

3.2 Document Location

TRIM Location	File Name
---------------	-----------

4 General Provisions

- All non-overdue antigens are due at the schedule points of 2, 4, 6, 12 and 18 months and 4, 12–13 and 14–16 years of age provided minimum intervals from previous doses have been met.
- Overdue antigen calculations are based on an interval of 28 days or 4 weeks except when the interval between doses is higher than 6 months then calendar months apply.
- Day of birth is counted as Day 0.
- Rules apply to all children living in Australia unless otherwise specified.
- The NICC provides catch-up advice for vaccines both recommended as per the Australian Immunisation Handbook as well as those funded under the NIP. Those incurring a cost to the patient (not funded under the NIP) will be indicated with a \$ sign.
- Some vaccines may not be funded under the NIP, but may be funded by an individual state or territory. These vaccines will be marked as at-cost (with a \$ sign) in the NICC.
- This guidance does not take into account situations where post-exposure prophylaxis is needed (e.g. tetanus). For these details please refer to the [Australian Immunisation Handbook](#).
- The NICC does not support the scheduling of vaccines while a person is undergoing cancer therapy. It can provide a catch-up schedule once the person is in remission and/or completed treatment.
- Tables have only been provided for younger age groups because at that age, how many doses a child needs is very dependent on what the child has had in the past and when. For older children, adolescents and young adults, the number of doses becomes simpler and this is covered in the text.

4.1 NICC Considerations/Exceptions

The NICC:

- will not accept history or provide recommendations for adults from their 20th birthday onwards
- will accept history for people vaccinated overseas but recommends catch-up based on the Australian schedule. Vaccines given overseas which are additional or different to the NIP schedule will be 'excluded' from the catch-up calculations.
- requires the user to flag whether a person has received vaccinations overseas to alert the user to be diligent in checking doses given and recommendations provided and provide additional information regarding overseas vaccines
- requires the user to flag that a person has medical at risk (MAR) factors to prompt the user to consider MAR factors
- will only be as accurate as the data entered by operators/user

4.2 Infanrix hexa Rule

When DTPa / IPV / Hib / Hep B are due and recommended within 4 weeks of each other, the antigens may be grouped together and administered on the latest date that any of the 6 antigens are recommended. (Note: DTP is always administered as a combination). Infanrix hexa will be presented as the singular choice when all 6 antigens are due (irrespective of the vaccination history, i.e. whether

the antigens were received as a combination or monovalent vaccines including overseas variants i.e. 'Generic/Other'). No other combinations to be presented. If one or more of the 6 Infanrix hexa antigens are NOT due together then other vaccine brand names can be provided (DTPa only, IPV only, Hep B only, Hib only, DTP-IPV).

4.3 Medical risk conditions Rule

If a person who has a medical risk condition completes the recommended vaccine schedule and then develops another medical risk condition with the same vaccine recommendations, they do not need to repeat the vaccine schedule. However, if the second medical risk condition has different vaccine recommendations, these should be given.

The only exception to this is for people receiving a haematopoietic stem cell transplant (HSCT). If a person who has a medical risk condition completes the recommended vaccine schedule and then receives a HSCT, they may need to repeat vaccination with vaccines already given for the original medical risk condition. This will be indicated in the individual vaccine guidance below.

4.4 Additional funding rules for vaccines

Outline any additional funding rules for vaccines, if relevant. For example vaccine brand X is funded, but vaccine brand Y is not.

4.5 Entering historical doses

Vaccination history can be provided using two ways.

- 'Antigens' pathway, where antigens are sorted by the NIP schedule order.
- 'Vaccines' pathway, where the vaccines are sorted in alphabetical order.

Each vaccination history record must include the date of vaccination and one or more vaccines/antigens given on that date.

Duplicate antigen/vaccine entries will be automatically removed.

The default setting displays age-appropriate Australian NIP vaccines/antigens.

To enter non-NIP doses, the 'Only show vaccines applicable for this person' toggle switch (which is 'on' by default) must be switched off.

4.6 Entering overseas doses

The default setting for both the 'Antigens' or 'Vaccines' pathways display age-appropriate Australian NIP vaccines/antigens.

To enter non-NIP doses, the 'Only show vaccines applicable for this person' toggle switch (which is 'on' by default) must be switched off.

To enter overseas doses (added as 'Generic/Other' variants), the 'Only show Australian NIP vaccines' toggle switch (which is 'on' by default) must be switched off.

5 Diphtheria-tetanus-acellular pertussis (DTPa)

5.1 Recommended schedule

5.1.1 All children and adolescents

- 3 primary doses of DTPa at 2, 4 and 6 months of age.
- Booster dose of DTPa at 18 months and 4 years of age
- Booster dose of dTpa from 11 years of age and by 14 years of age.

Note: To avoid confusion, the doses for DTPa should be labelled as Dose 1 of 5, Dose 2 of 5, Dose 3 of 5, Dose 4 of 5, and Dose 5 of 5.

5.1.2 Aboriginal and Torres Strait Islander children and adolescents

No additional recommendations.

5.1.3 People with specified medical conditions

People who have completed cancer therapy

- An additional booster dose of DTPa (if <10 years of age) or dTpa (≥10 years of age) after 6 months in remission or the completion of treatment (whichever is more recent), if previously fully vaccinated before commencing cancer therapy.
- If not fully vaccinated prior to cancer therapy, commence catch up as for healthy children and adolescents (instead of the booster dose), after 6 months in remission or the completion of treatment (whichever is more recent).

People who have had a haematopoietic stem cell transplant

- If <10 years of age, 3 doses of DTPa at 6, 8, 12 months post-transplant, and age dependent booster dose/s.
- If ≥10 years of age, 1 dose of dTpa at 6 months post-transplant, followed by 2 doses of dT at 8 and 12 months post-transplant.
- If any doses from the primary schedule were not received prior to transplant, these do not need to be given. However, for people <10 years of age, booster doses should be given, as per the routine schedule and catch-up for all children and adolescents.

People who are having/have had a solid organ transplant

- Where possible, children and adolescents should receive all routine scheduled doses at least 4 weeks before transplantation
- If any scheduled doses were not received prior to transplant, vaccination should recommence at least 6 months after transplant, as per the routine schedule and catch-up for all children and adolescents

5.2 Catch up dose parameters

5.2.1 All children and adolescents

Valid doses

Minimum age

- Minimum age dose 1 is 29 days.
- If dose 4 is administered at ≥ 3 years 6 months of age dose 5 is not required.
- If dose 5 is administered prior to 3 years 6 months of age it should not be repeated provided minimum intervals have been met.
- If ≥ 10 years of age, only 1 dose of dTpa is required, instead of any DTPa doses, followed by 2 doses of dT (any doses previously given should be deducted).

Minimum intervals

<10 years of age

- Minimum interval dose 1 - dose 2 is 4 weeks
- Minimum interval dose 2 - dose 3 is 4 weeks
- Minimum interval dose 3 - dose 4 for future recommendations is 6 calendar months.
- Minimum accepted interval dose 3 - dose 4 for doses already given is 181 days.
- Minimum interval dose 4 - dose 5 for future recommendations is 6 calendar months.
- Minimum accepted interval dose 4 - dose 5 for doses already given is 181 days.

NB: Apply the Infanrix hexa rule when appropriate.

≥ 10 years of age

- Minimum interval dose 1 dTpa - dose 2 dT is 4 weeks
- Minimum interval dose 2 dT - dose 3 dT is 4 weeks

Invalid doses

1st dose administered at ≤ 28 days of age

Message - Dose given at < minimum age

Minimum interval between any 2 doses not met

Message - Dose given at < minimum interval from previous dose

NB: An invalid dose is to be repeated at the correct schedule point or minimum interval from the previous valid dose if already overdue.

5.2.2 People with specified medical conditions

People who have completed cancer therapy

- If the routine childhood schedule has not been completed, refer to the catch-up parameters for all children and adolescents, commencing vaccination from 6 months after remission/end of treatment

Valid doses

Minimum intervals

- If the routine childhood schedule has been completed, minimum interval from remission/end of treatment - booster dose is 6 months

Invalid doses

Booster dose administered at <6 months from remission or end of treatment

Message - Dose given at < minimum interval from remission or end of treatment

NB: An invalid dose is to be repeated at the correct schedule point or minimum interval from the previous valid dose if already overdue.

People who have had a haematopoietic stem cell transplant

Valid doses

Minimum intervals

<10 years of age

- Minimum interval from transplant - dose 1 is 6 months
- Minimum interval dose 1 - dose 2 is 8 weeks
- Minimum interval dose 2 - dose 3 is 16 weeks
- Minimum interval dose 3 - dose 4 is 6 months
- Minimum interval dose 4 - dose 5 is 6 months

NB: Dose 5 not required if dose 4 given at ≥ 3.5 year of age

≥ 10 years of age

- Minimum interval from transplant - dose 1 is 6 months
- Minimum interval dose 1 - dose 2 is 8 weeks
- Minimum interval dose 2 - dose 3 is 16 weeks

Invalid doses

Booster dose administered at <6 months from transplant

Message - Dose given at < minimum interval from transplant

Minimum interval between any 2 doses not met

Message - Dose given at < minimum interval from previous dose

NB: An invalid dose is to be repeated at the correct schedule point or minimum interval from the previous valid dose if already overdue.

People who are having/have had a solid organ transplant

Before transplant, follow the catch-up schedule for all children and adolescents. No doses of vaccine should be given within 4 weeks of surgery.

After transplant, follow the guidance below:

Valid doses

Minimum intervals

- Minimum interval from transplant – next scheduled dose is 6 months
- At 6 months follow the catch-up schedule for all children and adolescents

Invalid doses

Dose administered at <6 months from transplant

Message - Dose given at < minimum interval from transplant

Minimum interval between any 2 doses not met

Message - Dose given at < minimum interval from previous dose

NB: An invalid dose is to be repeated at the correct schedule point or minimum interval from the previous valid dose if already overdue.

5.3 NIP funding

The following doses are funded for all children and adolescents <20 years of age, where required:

- 5 DTPa doses
- 1 dTpa dose
- 2 dT doses

6 Haemophilus Influenzae Type b (Hib) PRP-T

6.1 Recommended schedule

6.1.1 All children and adolescents

- 3 primary doses of Hib vaccine at 2, 4 and 6 months of age.
- Booster dose of Hib vaccine at 18 months of age

6.1.2 Aboriginal and Torres Strait Islander children and adolescents

No additional recommendations

6.1.3 People with specified medical conditions

People who have functional or anatomical asplenia (including sickle cell disease or other haemoglobinopathies)

- 1 dose of Hib vaccine at ≥5 years of age only if unvaccinated (have not had Hib vaccine before)
- For people having an elective splenectomy, where possible, they should receive all scheduled doses at least 2 weeks before surgery

People who have had a haematopoietic stem cell transplant

- 3 doses of Hib vaccine at 6, 8, 12 months post-transplant
- If any doses from the primary schedule have not been received prior to transplant, these do not need to be given

People who are having/have had a solid organ transplant

- Where possible, children and adolescents should receive all routine scheduled doses at least 4 weeks before transplantation
- If any scheduled doses were not received prior to transplant, vaccination should recommence at least 6 months after transplant, as per the routine schedule and catch-up for all children and adolescents

6.2 Catch up dose parameters

6.2.1 All children and adolescents

Valid doses

Minimum age

- Minimum age dose 1 is 29 days
- Minimum accepted age dose 4 for a dose already given is 11 months
- Minimum age dose 4 for future recommendations is 18 months

Maximum age

- Maximum age is 4 years (immediately prior to the 5th birthday)

Minimum intervals

- Minimum interval between primary doses at age <12 months is 4 weeks
- Minimum interval between last primary dose and booster dose is 8 weeks

NB: Apply the Infanrix hexa rule when appropriate.

Number of doses

The number of doses required depends on current age and previous doses received, see Catch-up schedule for Haemophilus influenzae type b (Hib) vaccination for children <5 years of age below

Invalid doses

1st dose administered at ≤ 28 days of age OR

4th dose administered at <11 months of age

Message - Dose given at < minimum age

4th dose administered at ≥ 11 months age but <18 months age

Message – No message to be displayed.

NB: This dose is not repeated at ≥ 18 months of age provided the minimum interval from the last primary dose has been met.

Minimum interval between any 2 doses not met

Message - Dose given at < minimum interval from previous dose

NB: An invalid dose is to be repeated at the correct schedule point or minimum interval from the previous valid dose if already overdue.

6.2.2 People with specified medical conditions

People who have functional or anatomical asplenia (including sickle cell disease or other haemoglobinopathies)

Before splenectomy, follow the catch-up schedule for all children and adolescents. No doses of vaccine should be given within 2 weeks of surgery.

After surgery, and for all other conditions, follow the guidance below:

Valid doses

Minimum age

- Minimum age dose 1 is 5 years if unvaccinated (not had any doses of this antigen)

Maximum age

- No maximum age limit

People who have had a haematopoietic stem cell transplant

Valid doses

Maximum age

- No maximum age limit

Minimum intervals

- Minimum interval from transplant - dose 1 is 6 months
- Minimum interval dose 1 - dose 2 is 8 weeks
- Minimum interval dose 2 - dose 3 is 16 weeks

Invalid doses

Booster dose administered at <6 months from transplant

Message - Dose given at < minimum interval from transplant

Minimum interval between any 2 doses not met

Message - Dose given at < minimum interval from previous dose

NB: An invalid dose is to be repeated at the correct schedule point or minimum interval from the previous valid dose if already overdue.

People who are having/have had a solid organ transplant

Before transplant, follow the catch-up schedule for all children and adolescents. No doses of vaccine should be given within 4 weeks of surgery.

After transplant, follow the guidance below:

Valid doses

Minimum intervals

- Minimum interval from transplant – next scheduled dose is 6 months
- At 6 months follow the catch-up schedule for all children and adolescents

Invalid doses

Dose administered at <6 months from transplant

Message - Dose given at < minimum interval from transplant

Minimum interval between any 2 doses not met

Message - Dose given at < minimum interval from previous dose

NB: An invalid dose is to be repeated at the correct schedule point or minimum interval from the previous valid dose if already overdue.

6.3 NIP funding

The 4 childhood doses are funded for all children.

The single dose of Hib vaccine for unvaccinated children who have functional or anatomical asplenia (including sickle cell disease or other haemoglobinopathies) aged ≥ 5 years of age is funded.

Catch-up schedule for Haemophilus influenzae type b (Hib) vaccination for children <5 years of age

Number of Hib doses received previously	Current age	Age at 1st dose of Hib vaccine	Age at 2nd dose of Hib vaccine	Age at 3rd dose of Hib vaccine	Number of further primary dose(s) needed	Number of booster doses needed at age ≥ 18 months, or 2 months after the last dose (whichever is later)
None	<7 months	N/A	N/A	N/A	3	1
	7–11 months	N/A	N/A	N/A	2	1
	12–17 months	N/A	N/A	N/A	1	1
	18–59 months	N/A	N/A	N/A	1	N/A
1	<12 months	<7 Months	N/A	N/A	2	1
	<12 months	7–11 months	N/A	N/A	1	1
	12–17 months	<12 months	N/A	N/A	1	1
	12–17 months	≥ 12 months	N/A	N/A	N/A	1
	18–59 months	<12 months	N/A	N/A	N/A	1
	18–59 months	12–17 months	N/A	N/A	N/A	1
	18–59 months	≥ 18 months	N/A	N/A	N/A	N/A
2	<12 months	<7 months	<12 months	N/A	1	1
	<12 months	7–11 months	7–11 months	N/A	N/A	1
	12–17 months	<12 months	Any age	N/A	N/A	1
	12–17 months	≥ 12 months	≥ 12 months	N/A	N/A	N/A
	18–59 months	<12 months	<12 months	N/A	N/A	1
	18–59 months	<12 months	12–17 months	N/A	N/A	1
	18–59 months	<12 months	12–17 months	N/A	N/A	N/A
	18–59 months	Any age	18–59 months	N/A	N/A	N/A
3	<17 months	<12 months	<12 months	<12 months	N/A	1
	12–17 months	At least 1 dose (most likely 3rd dose) at 12–17 months	At least 1 dose (most likely 3rd dose) at 12–17 months	At least 1 dose (most likely 3rd dose) at 12–17 months	N/A	N/A
	18–59 months	<12 months	<12 months	<12 months	N/A	1
	18–59 months	At least 1 dose at ≥ 12 months	At least 1 dose at ≥ 12 months	At least 1 dose at ≥ 12 months	N/A	N/A

N/A = Not Applicable

7 Hepatitis A

7.1 Recommended schedule

7.1.1 Non-Aboriginal and Torres Strait Islander children in all states and Aboriginal and Torres Strait Islander children in ACT, NSW, TAS & VIC

No recommendations

7.1.2 Aboriginal and Torres Strait Islander children in NT, QLD, SA or WA

- 2 doses of Hep A vaccine at 18 months and 4 years of age

7.1.3 People with specified medical conditions in all states and territories

People who have a developmental disability

- 2 doses of Hep A vaccine with a 6-month interval, if not previously vaccinated

People who have chronic liver disease (including chronic hepatitis, cirrhosis or biliary atresia) or who have had a liver transplant

- 2 doses of Hep A vaccine with a 6-month interval, if not previously vaccinated
- Where possible, children and adolescents should receive all routine scheduled doses at least 4 weeks before transplantation
- If any scheduled doses were not received prior to transplant, vaccination should recommence at least 6 months after transplant, as per the routine schedule and catch-up for all children and adolescents

7.2 Catch up dose parameters

7.2.1 Aboriginal and Torres Strait Islander children in NT, QLD, SA or WA

Valid doses

Minimum age

- Minimum age dose 1 is 12 months
- Minimum age dose 2 is 18 months

Maximum age

- Maximum age is 9 years (immediately prior to the 10th birthday)

Minimum intervals

- Minimum interval dose 1 - dose 2 for future recommendations is 6 calendar months.

- Minimum accepted interval dose 1 – dose 2 for doses already given is 181 days

Invalid doses

1st dose administered at < 12 months of age:

Message - Dose given at < minimum age

Minimum interval between any 2 doses not met

Message - Dose given at < minimum interval from previous dose

NB: An invalid dose is to be repeated at the correct schedule point or minimum interval from the previous valid dose.

7.2.2 People with specified medical conditions in all states and territories

People who have a developmental disability

Valid doses

Minimum age

- Minimum age dose 1 is 12 months

Minimum intervals

- Minimum interval dose 1 - dose 2 for future recommendations is 6 calendar months.
- Minimum accepted interval dose 1 – dose 2 for doses already given is 181 days
- The minimum interval for people with specified medical conditions should over-ride the dose 2 minimum age and interval for Aboriginal and Torres Strait Islander children in NT, QLD, SA or WA

Invalid doses

1st dose administered at < 12 months of age:

Message - Dose given at < minimum age

Minimum interval between any 2 doses not met

Message - Dose given at < minimum interval from previous dose

NB: An invalid dose is to be repeated at the correct schedule point or minimum interval from the previous valid dose.

People who have chronic liver disease (including chronic hepatitis, cirrhosis or biliary atresia) or who have had a liver transplant

Before transplant, follow the catch-up schedule for Aboriginal and Torres Strait Islander children in NT, QLD, SA or WA. No doses of vaccine should be given within 4 weeks of surgery.

After transplant, follow the guidance below:

Valid doses

Minimum intervals

- Minimum interval from transplant – next scheduled dose is 6 months

- Minimum accepted interval dose 1 – dose 2 for doses already given is 181 days
- The minimum interval for people with specified medical conditions should over-ride the dose 2 minimum age and interval for Aboriginal and Torres Strait Islander children in NT, QLD, SA or WA

Invalid doses

Dose administered at <6 months from transplant

Message - Dose given at < minimum interval from transplant

Minimum interval between any 2 doses not met

Message - Dose given at < minimum interval from previous dose

NB: An invalid dose is to be repeated at the correct schedule point or minimum interval from the previous valid dose if already overdue.

7.3 NIP funding

All scheduled childhood doses are funded for Aboriginal and Torres Strait Islander children.

8 Hepatitis B

8.1 Recommended schedule

8.1.1 All children and adolescents

- Birth dose of paediatric formulation Hep B vaccine between 0 and 7 days
- 3 Primary doses of paediatric formulation Hep B vaccine at 2, 4 and 6 months of age.

8.1.2 Aboriginal and Torres Strait Islander children and adolescents

No additional recommendations

8.1.3 People with specified medical conditions

People who have completed cancer therapy

- An additional booster dose of paediatric formulation Hep B vaccine after 6 months in remission or the completion of treatment (whichever is more recent), if previously fully vaccinated before commencing cancer therapy
- If not fully vaccinated prior to cancer therapy, commence catch-up as for healthy children (instead of the booster dose), after 6 months in remission or the completion of treatment (whichever is most recent)

People who have had a haematopoietic stem cell transplant

- 3 doses of adult formulation Hep B vaccine at 6, 8, 12 months post-transplant
- If any doses from the primary schedule have not been received prior to transplant, these do not need to be given

People who are having/have had a solid organ transplant

- Where possible, children and adolescents should receive all routine scheduled doses at least 4 weeks before transplantation
- If any scheduled doses were not received prior to transplant, vaccination should recommence at least 6 months after transplant, as per the routine schedule and catch-up for all children

People who have a HIV infection

- Follow the recommended schedule for all children and adolescents
- Any doses given after diagnosis should be using the adult formulation Hep B vaccine

People who have chronic liver disease

- Follow the recommended schedule for all children and adolescents
- Any doses given after diagnosis should be using the adult formulation Hep B vaccine

Children who were premature (<32 weeks gestation)/low birth weight infants (<2000g)

- An additional booster dose of paediatric formulation Hep B vaccine at 12 months of age

8.2 Catch up dose parameters

8.2.1 All children and adolescents

Valid doses

Birth Dose

- Catch-up of the birth dose is not required, however this dose (if given) may be assessed as the first dose (often for children vaccinated overseas) and a child can be considered fully vaccinated, if they have already received 3 doses at birth, 1-2 months of age and ≥ 6 months of age
- Minimum age birth dose is 0 days
- Maximum age birth dose is 7 days

Minimum age

- Minimum age dose 1 is 29 days
- Minimum accepted age dose 3 for doses already given is 24 weeks

Number of doses

- Healthy adolescents 11–15 years of age requiring catch-up can have a 2-dose schedule using adult formulation Hep B vaccine, as an alternative to a 3-dose schedule using paediatric formulation Hep b vaccine

Minimum intervals

3-dose schedule

- Minimum interval dose 1 - dose 2 is 4 weeks
- Minimum interval dose 2 - dose 3 is 8 weeks
- Minimum interval dose 1 - dose 3 is 16 weeks

2-dose schedule

- Minimum interval dose 1 - dose 2 is 16 weeks

Catch-up of the birth dose is not required

NB: Apply the Infanrix hexa rule when appropriate.

Invalid doses

Birth dose administered at >7 days and ≤ 28 days of age OR

1st dose administered at ≤ 28 days of age

Message - Dose given at $<$ minimum age

Minimum interval between any 2 doses not met

Message - Dose given at $<$ minimum interval from previous dose

NB: An invalid dose is to be repeated at the correct schedule point or minimum interval from the previous valid dose if already overdue.

8.2.2 People with specified medical conditions

People who have completed cancer therapy

- If the routine childhood schedule has not been completed, refer to the catch-up parameters for all children and adolescents

Valid doses

Minimum intervals

- If the routine childhood schedule has been completed, minimum interval from remission/end of treatment - booster dose is 6 months

Invalid doses

Booster dose administered at <6 months from remission or end of treatment

Message - Dose given at < minimum interval from remission or end of treatment

NB: An invalid dose is to be repeated at the correct schedule point or minimum interval from the previous valid dose if already overdue.

People who have had a haematopoietic stem cell transplant

Valid doses

Minimum intervals

- Minimum interval from transplant - dose 1 is 6 months
- Minimum interval dose 1 - dose 2 is 8 weeks
- Minimum interval dose 2 - dose 3 is 16 weeks

Invalid doses

Booster dose administered at <6 months from transplant

Message - Dose given at < minimum interval from transplant

Minimum interval between any 2 doses not met

Message - Dose given at < minimum interval from previous dose

NB: An invalid dose is to be repeated at the correct schedule point or minimum interval from the previous valid dose if already overdue.

People who are having/have had a solid organ transplant

Before transplant, follow the catch-up schedule for all children and adolescents. No doses of vaccine should be given within 4 weeks of surgery.

After transplant, follow the guidance below:

Valid doses

Minimum intervals

- Minimum interval from transplant – next scheduled dose is 6 months
- At 6 months follow the catch-up schedule for all children and adolescents

Invalid doses

Dose administered at <6 months from transplant

Message - Dose given at < minimum interval from transplant

Minimum interval between any 2 doses not met

Message - Dose given at < minimum interval from previous dose

NB: An invalid dose is to be repeated at the correct schedule point or minimum interval from the previous valid dose if already overdue.

People who have a HIV infection

Refer to the catch-up parameters for all children and adolescents

People who have chronic liver disease

Refer to the catch-up parameters for all children and adolescents

People who were premature (<32 weeks gestation)/low birth weight infants (<2000g)

Valid doses

Minimum intervals

- If the routine childhood schedule has been completed, the minimum interval from dose 3 to the booster dose is 6 months

Invalid doses

Minimal interval between dose 3 and booster dose not met

Message - Dose given at < minimum interval from previous dose

NB: An invalid dose is to be repeated at the correct schedule point or minimum interval from the previous valid dose if already overdue.

8.3 NIP funding

The birth dose and 3 further doses are funded for all people <20 years of age.

9 Human Papillomavirus (HPV)

9.1 Recommended schedule

9.1.1 All adolescents

- 1 dose of HPV vaccine at 12–13 years of age

9.1.2 Aboriginal and Torres Strait Islander people

No additional recommendations

9.1.3 Adolescents with specified medical conditions

Adolescents who have a significant immunocompromising condition

- Two additional doses of HPV vaccine, at a 2-month interval following dose 1, and 4-month interval following dose 2

Specified medical conditions for which an additional dose of HPV vaccine is scheduled

primary or secondary immunodeficiencies (complete or partial deficiencies of B-lymphocyte antibody or T-lymphocytes)

haematological malignancies

non-haematological malignancies receiving chemotherapy or radiotherapy (currently or anticipated)

previous solid organ transplant

HIV infection

significant immunosuppressive therapy (current or anticipated)

Adolescents who have had a haematopoietic stem cell transplant

- 3 doses of HPV vaccine at 8, 12, 24 months post-transplant
- If any doses from the primary schedule have not been received prior to transplant, these do not need to be given

9.2 Catch up dose parameters

9.2.1 All adolescents

Valid doses

Minimum age

- Minimum age dose 1 is 9 years

Maximum age

- Maximum age is 19 years (immediately prior to the 20th birthday)

Invalid doses

Dose administered at <9 years of age:

Message - Dose given at < minimum age

NB: An invalid dose is to be repeated at the correct schedule point or minimum interval from the previous valid dose.

9.2.2 Adolescents with specified medical conditions

Adolescents who have a significant immunocompromising condition

Valid doses

Minimum age

- Minimum age dose 1 is 9 years

Maximum age

- Maximum age is 19 years (immediately prior to the 20th birthday)

Number of doses

- If an adolescent had received 1 dose of HPV vaccine prior to solid organ transplant, no further doses are necessary after transplant.

Minimum intervals

- Minimum interval dose 1 - dose 2 for future recommendations is 4 weeks
- Minimum interval dose 1 - dose 2 for doses already given is 28 days
- Minimum interval dose 2 - dose 3 for future recommendations is 12 weeks
- Minimum interval dose 2 - dose 3 for doses already given is 84 days
- Minimum interval dose 1 - dose 3 for future recommendations is 5 calendar months
- Minimum interval dose 2 - dose 3 for doses already given is 151 days

Invalid doses

1st dose administered at <9 years of age:

Message - Dose given at < minimum age

Minimum interval between any 2 doses not met

Message - Dose given at < minimum interval from previous dose

NB: An invalid dose is to be repeated at the correct schedule point or minimum interval from the previous valid dose.

Adolescents who have had a haematopoietic stem cell transplant

Valid doses

Minimum age

- Minimum age dose 1 is 9 years

Maximum age

- Maximum age is 19 years (immediately prior to the 20th birthday)

Minimum intervals

- Minimum interval from transplant - dose 1 is 8 months
- Minimum interval dose 1 - dose 2 is 16 weeks
- Minimum interval dose 2 - dose 3 is 12 months

Invalid doses

Booster dose administered at <8 months from transplant

Message - Dose given at < minimum interval from transplant

Minimum interval between any 2 doses not met

Message - Dose given at < minimum interval from previous dose

NB: An invalid dose is to be repeated at the correct schedule point or minimum interval from the previous valid dose if already overdue.

9.3 NIP funding

One dose is funded for all adolescents aged <20 years. Three doses are funded for adolescents who have a significant immunocompromising condition.

10 Inactivated poliomyelitis vaccine (IPV)

10.1 Recommended schedule

10.1.1 All children and adolescents

- 3 primary doses of IPV at 2, 4 and 6 months of age.
- Booster dose of IPV at 4 years of age

10.1.2 Aboriginal and Torres Strait Islander children and adolescents

No additional recommendations

10.1.3 People with specified medical conditions

People who have had a haematopoietic stem cell transplant

- 3 doses of IPV at 6, 8, 12 months post-transplant
- If any doses from the primary schedule have not been received prior to transplant, these do not need to be given

People who are having/have had a solid organ transplant

- Where possible, children and adolescents should receive all routine scheduled doses at least 4 weeks before transplantation
- If any scheduled doses were not received prior to transplant, vaccination should recommence at least 6 months after transplant, as per the routine schedule and catch-up for all children and adolescents

10.2 Catch up dose parameters

10.2.1 All children and adolescents

Valid doses

Minimum age

- Minimum age dose 1 is 29 days
- Minimum age dose 4 is 3 years 6 months
- If dose 3 is administered at ≥ 4 years of age dose 4 is not required.

Minimum intervals

- Minimum interval dose 1 - dose 2 is 4 weeks
- Minimum interval dose 2 - dose 3 is 4 weeks
- Minimum interval dose 3 - dose 4 is 4 weeks

NB: Apply the Infanrix hexa rule when appropriate.

Invalid doses

1st dose administered at ≤ 28 days of age

4th dose administered at < 4 years of age

Message - Dose given at $<$ minimum age

Minimum interval between any 2 doses not met

Message - Dose given at $<$ minimum interval from previous dose

NB: An invalid dose is to be repeated at the correct schedule point or minimum interval from the previous valid dose if already overdue.

10.2.2 People with specified medical conditions

People who have had a haematopoietic stem cell transplant

Valid doses

Minimum intervals

- Minimum interval from transplant - dose 1 is 6 months
- Minimum interval dose 1 - dose 2 is 8 weeks
- Minimum interval dose 2 - dose 3 is 16 weeks

Invalid doses

Booster dose administered at < 6 months from transplant

Message - Dose given at $<$ minimum interval from transplant

Minimum interval between any 2 doses not met

Message - Dose given at $<$ minimum interval from previous dose

NB: An invalid dose is to be repeated at the correct schedule point or minimum interval from the previous valid dose if already overdue.

People who are having/have had a solid organ transplant

Before transplant, follow the catch-up schedule for all children and adolescents. No doses of vaccine should be given within 4 weeks of surgery.

After transplant, follow the guidance below:

Valid doses

Minimum intervals

- Minimum interval from transplant – next scheduled dose is 6 months
- At 6 months follow the catch-up schedule for all children and adolescents

Invalid doses

Dose administered at < 6 months from transplant

Message - Dose given at $<$ minimum interval from transplant

Minimum interval between any 2 doses not met

Message - Dose given at < minimum interval from previous dose

NB: An invalid dose is to be repeated at the correct schedule point or minimum interval from the previous valid dose if already overdue.

10.3 NIP funding

All doses are funded for people <20 years of age

11 Influenza

11.1 Recommended schedule

11.1.1 All people

- 1 dose of influenza vaccine each year if ≥ 6 months of age
- If < 9 years of age and receiving influenza vaccine for the first time, 2 doses of influenza vaccine

11.1.2 Aboriginal and Torres Strait Islander people

No additional recommendations

11.1.3 People with specified medical conditions

People who have had a solid organ transplant

- 2 doses of influenza vaccine in the first year post-transplant

People who have had a haematopoietic stem cell transplant

- 2 doses of influenza vaccine in the first year post-transplant, commencing at least 6 months post-transplant

11.2 Catch up dose parameters

11.2.1 All people

Valid doses

Minimum age

- Minimum age is 6 months

Minimum intervals

- Minimum interval dose 1 - dose 2 is 4 weeks

Invalid doses

1st dose administered at ≤ 6 months of age

Message - Dose given at $<$ minimum age

Minimum interval between any 2 doses not met

Message - Dose given at $<$ minimum interval from previous dose

NB: An invalid dose is to be repeated at the correct schedule point or minimum interval from the previous valid dose if already overdue.

11.2.2 People with specified medical conditions

People who have had a solid organ transplant

Valid doses

Minimum intervals

- Minimum interval dose 1 - dose 2 is 4 weeks

Invalid doses

Minimum interval between any 2 doses not met

Message - Dose given at < minimum interval from previous dose

NB: An invalid dose is to be repeated at the correct schedule point or minimum interval from the previous valid dose if already overdue.

People who have had a haematopoietic stem cell transplant

Valid doses

Minimum intervals

- Minimum interval from transplant - dose 1 is 6 months
- Minimum interval dose 1 - dose 2 is 4 weeks

Invalid doses

Booster dose administered at <6 months from transplant

Message - Dose given at < minimum interval from transplant

Minimum interval between any 2 doses not met

Message - Dose given at < minimum interval from previous dose

NB: An invalid dose is to be repeated at the correct schedule point or minimum interval from the previous valid dose if already overdue.

11.3 NIP funding

Influenza doses are funded for all children <5 years of age and all Aboriginal and Torres Strait Islander children. The following children with specified medical conditions are eligible for funded doses regardless of age:

- Functional or anatomical asplenia, including sickle cell disease or other haemoglobinopathies
- Immunocompromising conditions
- Chronic respiratory disease
- Cardiac disease
- Chronic renal failure
- Long-term aspirin therapy in children aged 6 months to 10 years
- Chronic neurological conditions
- Chronic metabolic disorders

12 Measles-Mumps-Rubella (MMR)

12.1 Recommended schedule

NB: Please read MMR rules in conjunction with Varicella rules.

Some children may receive a dose of MMR between 6 and 12 months of age if travelling to an area of high measles prevalence. This dose does not count toward the recommended doses below.

12.1.1 All children and adolescents

- 2 doses of MMR containing vaccine at 12 and 18 months of age

12.1.2 Aboriginal and Torres Strait Islander children and adolescents

No additional recommendations

12.1.3 People with specified medical conditions

People who have completed cancer therapy

- A booster dose of MMR after 6 months in remission or the completion of treatment (whichever is more recent), if previously fully vaccinated before commencing cancer therapy
- Serological immunity reviewed 6 weeks later, administer a second booster dose of MMR at 8 months if required
- If 1 dose previously given, 1 dose as per the schedule for healthy children, after 6 months in remission or the completion of treatment (whichever is more recent)
- If previously unvaccinated, 2 doses as per the schedule for healthy children, after 6 months in remission or the completion of treatment (whichever is more recent)

People who have had a haematopoietic stem cell transplant

- 2 doses of MMR at 24 months post-transplant, with a 4 week interval between doses
- Serological immunity reviewed 4 weeks after dose 2, to confirm seroconversion
- If any doses from the schedule have not been received prior to transplant, these do not need to be given

People who are having a solid organ transplant

- Where possible, children and adolescents should receive all routine scheduled doses at least 4 weeks before transplantation
- Vaccination is contraindicated after transplantation

People who are severely immunocompromised

- Vaccination is contraindicated for children and adolescents with the following conditions: congenital or acquired immune deficiency, haematological malignancies, receiving chemotherapy or radiotherapy (currently or anticipated), HIV infection with an age-specific CD4+ count <15% of total lymphocytes, immunosuppressive therapy (current or anticipated)

12.2 Catch up dose parameters

12.2.1 All children and adolescents

Valid doses

Minimum age

- Minimum age dose 1 for future recommendations is 12 months
- Minimum accepted age dose 1 for dose already given is 11 months
- Minimum age dose 2 for future recommendations is 18 months
- Minimum accepted age dose 2 for dose already given is 12 months

Minimum intervals

- Minimum interval between any MMR or MMR-Varicella vaccine and another live vaccine is 4 weeks, unless the live vaccines are administered on the same day

MMR

- MMR only **MUST** be recommended as the first dose of MMR containing vaccine in any child ≥ 12 months < 4 years of age followed by dose 2 as MMRV at 18 months age or 4 weeks after dose 1 if the dose is already overdue.

MMRV

- MMRV is recommended as the first dose of MMR containing vaccine in any child ≥ 4 years of age who also requires varicella vaccine, followed by dose 2 as MMR only vaccine 4 weeks after dose 1.
- MMRV should not be used for any dose in people ≥ 14 years of age

MMR and Varicella

- If a person has received dose 1 of MMR AND monovalent varicella at ≥ 12 months of age observing the 4-week minimum interval, MMR and monovalent varicella will be recommended as dose 2.
- If a person has received dose 1 and dose 2 of MMR at ≥ 12 months AND dose 1 and dose 2 of monovalent varicella observing 4-week minimum intervals, no further doses will be recommended.

Invalid doses

1st dose administered at < 11 months of age:

Message - Dose given at $<$ minimum age

1st dose administered at ≥ 11 - < 12 months age

Message – No message to be displayed.

NB: This dose is not repeated at ≥ 12 months of age

Minimum interval between any dose MMR and / or Varicella containing vaccine not met

Message - Dose given at $<$ minimum interval from previous dose

NB: An invalid dose is to be repeated at the correct schedule point or minimum interval from the previous invalid dose if already overdue.

12.2.2 People with specified medical conditions

People who have completed cancer therapy

- If the routine childhood schedule has not been completed, refer to the catch-up parameters for all children

Valid doses

Minimum intervals

- If the routine childhood schedule has been completed, minimum interval from remission/end of treatment - booster dose is 6 months

Invalid doses

Booster dose administered at <6 months from remission or end of treatment

Message - Dose given at < minimum interval from remission or end of treatment

NB: An invalid dose is to be repeated at the correct schedule point or minimum interval from the previous invalid dose if already overdue.

People who have had a haematopoietic stem cell transplant

Valid doses

Minimum intervals

- Minimum interval from transplant - dose 1 is 24 months
- Minimum interval from dose 1 - dose 2 is 4 weeks

Invalid doses

Booster dose administered at <24 months from transplant

Message - Dose given at < minimum interval from transplant

NB: An invalid dose is to be repeated at the correct schedule point or minimum interval from the previous invalid dose if already overdue.

People who are having a solid organ transplant

Prior to surgery, follow the catch-up schedule for all children and adolescents. No doses of vaccine should be given after surgery.

12.3 NIP funding

Two doses are funded for all people <20 year of age

13 Meningococcal ACWY Conjugate (MenACWY)

13.1 Recommended schedule

13.1.1 All children and adolescents

- 3 doses of MenACWY vaccine at 2, 4 and 12 months of age
- 1 dose of MenACWY vaccine at 15–19 years of age

13.1.2 Aboriginal and Torres Strait Islander children

No additional recommendations

13.1.3 People with specified medical conditions

People who have specified medical conditions listed in the table below

- 4 doses of MenACWY vaccine at 2, 4, 6 and 12 months of age, instead of the usual 3 doses for all children and adolescents
- If ≤6 years of age, a first booster dose 3 years after completing the primary schedule, and a second booster dose 5 years later
- If ≥7 years of age, a booster dose 5 years after completing the primary schedule
- For people having an elective splenectomy, where possible, they should receive scheduled doses at least 2 weeks before surgery

People who have completed cancer therapy

- An additional booster dose of MenACWY vaccine after 6 months in remission or the completion of treatment (whichever is more recent), if previously fully vaccinated before commencing cancer therapy
- If not fully vaccinated prior to cancer therapy, commence catch-up as for healthy children and adolescents (instead of the booster dose), after 6 months in remission or the completion of treatment (whichever is most recent)

People who have had a haematopoietic stem cell transplant

- If <12 months of age, 3 primary doses of MenACWY vaccine from 6 months post-transplant, following schedule for people who have specified medical conditions and no previous doses
- If ≥12 months of age, 2 primary doses of MenACWY vaccine from 6 months post-transplant, following schedule for children who have specified medical conditions and no previous doses
- If ≤6 years of age, a first booster dose 3 years after completing the primary schedule, and a second booster dose 5 years after the first booster dose
- If ≥7 years of age, a booster dose 5 years after completing the primary schedule

People who are having/have had a solid organ transplant

- Where possible, children and adolescents should receive all routine scheduled doses at least 4 weeks before transplantation

- If any scheduled doses were not received prior to transplant, vaccination should recommence at least 6 months after transplant, as per the routine schedule and catch-up for all children and adolescents

Specified medical conditions for which additional doses of MenACWY vaccine are scheduled.

functional or anatomical asplenia, including sickle cell disease or other haemoglobinopathies

defects in, or deficiency of, complement components, including factor H, factor D or properdin deficiency

current or planned future treatment with eculizumab

HIV infection

13.2 Catch up dose parameters

13.2.1 All children and adolescents

Valid doses

Minimum age

If a valid MenC vaccine has already been given at ≥ 11 months age, MenACWY is not required unless the child is born on or after 1/7/2017, or is >14 years of age.

MenACWY

Children <10 years of age

- Minimum age dose 1 is 29 days
- Minimum accepted age for dose 3 already given is 11 months
- Minimum age dose 3 for future recommendations is 12 months

Adolescents

- Minimum accepted age for dose already given is 14 years
- Minimum age for future recommendations is 15 years

MenC

- Minimum accepted age for dose already given is 11 months

Minimum intervals

- Minimum interval between primary doses of MenACWY is 8 weeks
- Minimum interval between dose of MenC and MenACWY is 8 weeks

Number of doses

Children <10 years of age

- MenACWY vaccine should be used for catch-up
- The number of doses required depends on current age and previous doses received, see MenACWY vaccine catch-up for healthy children aged <10 years below

Adolescents

- MenACWY vaccine should be used for catch-up

- 1 dose of MenACWY vaccine required if 0 previous doses of MenACWY received since age 14 years

Invalid doses

1st dose administered at ≤ 28 days of age

Message - Dose given at < minimum age

Minimum interval between any 2 doses not met

Message - Dose given at < minimum interval from previous dose

NB: An invalid dose is to be repeated at the correct schedule point or minimum interval from the previous valid dose if already overdue.

MenACWY vaccine catch-up for healthy children aged <10 years*

Number of doses given previously	Age at presentation	Age when previous dose of MenACWY was given			Recommendation
		1st dose	2nd dose	3rd dose	Number of further dose(s) required
No previous doses	<6 months	–	–	–	3
	6–<12 months	–	–	–	2
	≥ 12 months	–	–	–	1
1 previous dose	<12 months	<6 months	–	–	2
	6–<12 months	6–<12 months	–	–	1
	≥ 12 months	<12 months	–	–	1
	≥ 12 months	≥ 12 months	–	–	None
2 previous doses	<12 months	<12 months	<12 months	–	1
	≥ 12 months	<12 months	<12 months	–	1
	≥ 12 months	Any age	≥ 12 months	–	None
3 previous doses	<12 months	<12 months	<12 months	<12 months	1
	≥ 12 months	<12 months	<12 months	<12 months	1
	≥ 12 months	Any age	Any age	≥ 12 months	None

*No upper age limit for Aboriginal and Torres Strait Islander children

13.2.2 People with specified medical conditions

People who have specified medical conditions listed in the table above

Before splenectomy, follow the catch-up schedule for all children and adolescents. No doses of vaccine should be given within 2 weeks of surgery.

After surgery, and for all other conditions, follow the guidance below:

Valid doses

Minimum age

- Minimum age dose 1 is 29 days
- Minimum accepted age for dose 4 already given is 11 months
- Minimum age dose 4 for future recommendations is 12 months
- Minimum age for booster dose is 4 years

Minimum intervals

- Minimum interval between primary doses is 8 weeks
- If ≤ 6 years of age, minimum interval between last primary dose and first booster dose is 3 years
- If ≥ 7 years of age, minimum interval between last primary dose and first booster dose is 5 years
- Minimum interval between first booster dose and second booster dose is 5 years
- Minimum interval between any previous dose of MenACWY polysaccharide vaccine and a MenACWY conjugate vaccine is 2 years

Number of doses

- The number of doses required depends on current age and previous doses received, see MenACWY vaccine primary catch-up for people with specified medical conditions below
- Booster doses in people with specified medical conditions should continue at 5-yearly intervals, there is no upper limit to the number of vaccine doses.

Invalid doses

1st dose administered at ≤ 28 days of age

Message - Dose given at < minimum age

Minimum interval between any 2 doses not met

Message - Dose given at < minimum interval from previous dose

NB: An invalid dose is to be repeated at the correct schedule point or minimum interval from the previous valid dose if already overdue.

People who have completed cancer therapy

- If the routine childhood schedule has not been completed, refer to the catch-up parameters for all children and adolescents

Valid doses

Minimum intervals

- If the routine childhood schedule has been completed, minimum interval from remission/end of treatment - booster dose is 6 months

Invalid doses

Booster dose administered at <6 months from remission or end of treatment

Message - Dose given at < minimum interval from remission or end of treatment

NB: An invalid dose is to be repeated at the correct schedule point or minimum interval from the previous valid dose if already overdue.

People who have had a haematopoietic stem cell transplant

Valid doses

Minimum intervals

- Minimum interval from transplant - dose 1 is 6 months
- Minimum interval dose 1 - dose 2 is 8 weeks
- Minimum interval dose 2 - dose 3 is 8 weeks (only required if vaccination commenced at 6–11 months of age)
- If ≤6 years of age, minimum interval between last primary dose and booster dose is 3 years
- If ≥7 years of age, minimum interval between last primary dose and booster dose is 5 years
- Minimum interval between first booster dose and second booster dose is 5 years

Invalid doses

Dose administered at <6 months from transplant

Message - Dose given at < minimum interval from transplant

Minimum interval between any 2 doses not met

Message - Dose given at < minimum interval from previous dose

NB: An invalid dose is to be repeated at the correct schedule point or minimum interval from the previous valid dose if already overdue.

People who are having/have had a solid organ transplant

Before transplant, follow the catch-up schedule for all children and adolescents. No doses of vaccine should be given within 4 weeks of surgery.

After transplant, follow the guidance below:

Valid doses

Minimum intervals

- Minimum interval from transplant – next scheduled dose is 6 months
- At 6 months follow the catch-up schedule for all children and adolescents

Invalid doses

Dose administered at <6 months from transplant

Message - Dose given at < minimum interval from transplant

Minimum interval between any 2 doses not met

Message - Dose given at < minimum interval from previous dose

NB: An invalid dose is to be repeated at the correct schedule point or minimum interval from the previous valid dose if already overdue.

MenACWY vaccine primary catch-up for people with specified medical conditions

Number of primary doses given previously	Age at presentation	Age when previous dose of MenACWY was given				Recommendation Number of further primary dose(s) required
		1st dose	2nd dose	3rd dose	4th dose	
No previous doses	<6 months	–	–	–	–	4
	6–<12 months	–	–	–	–	3
	≥12 months	–	–	–	–	2
1 previous dose	<12 months	<6 months	–	–	–	3
	6–<12 months	6–<12 months	–	–	–	2
	≥12 months	<12 months	–	–	–	2
	≥12 months	≥12 months	–	–	–	1
2 previous doses	<12 months	<6 months	<12 months	–	–	2
	<12 months	6–<12 months	6–<12 months	–	–	1
	≥12 months	<6 months	<12 months	–	–	2
	≥12 months	6–<12 months	6–<12 months	–	–	1
	≥12 months	Any age	≥12 months	–	–	1
3 previous doses	<12 months	<12 months	<12 months	<12 months	–	1
	≥12 months	<12 months	<12 months	<12 months	–	1
	≥12 months	<6 months	<12 months	≥12 months	–	1
	≥12 months	6–<12 months	<12 months	≥12 months	–	None
	≥12 months	Any age	≥12 months	≥12 months	–	None

13.3 NIP funding

One dose of MenACWY vaccine funded for all children at 12 months of age and another dose is funded for adolescents at 14–16 years of age.

People with the following specified medical conditions are eligible for all required doses to be funded:

- Functional or anatomical asplenia, including sickle cell disease or other haemoglobinopathies
- defects in, or deficiency of, complement components, including factor H, factor D or properdin deficiency
- current or future treatment with eculizumab

14 Meningococcal B (MenB)

14.1 Recommended schedule

14.1.1 All children and adolescents

- 3 doses of MenB vaccine at 2, 4 and 12 months of age
- 2 doses of MenB vaccine at 15–19 years of age

14.1.2 Aboriginal and Torres Strait Islander children

No additional recommendations

14.1.3 People with specified medical conditions

People who have specified medical conditions listed in the table below

- 4 doses of MenB vaccine at 2, 4, 6 and 12 months of age, instead of the usual 3 doses for all children and adolescents
- If ≤ 6 years of age, a booster dose 3 years after completing the primary schedule
- If ≥ 7 years of age, a booster dose 5 years after completing the primary schedule
- For people having an elective splenectomy, where possible, they should receive scheduled doses at least 2 weeks before surgery

People who have had a haematopoietic stem cell transplant

- If < 12 months of age, 3 doses of MenB vaccine from 6 months post-transplant, following schedule for people who have specified medical conditions and no previous doses
- If ≥ 12 months of age and receiving Bexsero, 2 doses of MenB vaccine from 6 months post-transplant, following schedule for children who have specified medical conditions and no previous doses
- If ≥ 12 months of age and receiving Trumenba, 3 doses of MenB vaccine from 6 months post-transplant, following schedule for children who have specified medical conditions and no previous doses

People who are having/have had a solid organ transplant

- Where possible, children and adolescents should receive all routine scheduled doses at least 4 weeks before transplantation
- If any scheduled doses were not received prior to transplant, vaccination should recommence at least 6 months after transplant, as per the routine schedule and catch-up for all children and adolescents

Specified medical conditions for which additional doses of MenB vaccine are scheduled.

functional or anatomical asplenia, including sickle cell disease or other haemoglobinopathies

defects in, or deficiency of, complement components, including factor H, factor D or properdin deficiency

current or planned future treatment with eculizumab

HIV infection

14.2 Catch up dose parameters

14.2.1 All children and adolescents

Valid doses

Minimum age

Children <2 years of age

- Minimum age dose 1 is 29 days
- Minimum accepted age for dose 3 already given is 11 months
- Minimum age dose 3 for future recommendations is 12 months

Adolescents 15–19 years

- Minimum accepted age for dose 1 already given is 14 years
- Minimum age dose 1 for future recommendations is 15 years

Minimum intervals

- Minimum interval between doses is 6 weeks if <6 months of age
- Minimum interval between doses is 8 weeks if 6–23 months of age for receipt of Bexsero
- Minimum interval between doses is 4 weeks if ≥2 years of age for receipt of Bexsero
- Minimum interval between doses is 6 months if ≥10 years of age for receipt of Trumenba

Number of doses

Children <2 years of age

- The number of doses required depends on current age and previous doses received, see MenB vaccine catch-up for healthy children aged <2 years below

Adolescents 15–19 years

- 2 doses of MenB vaccine required if 0 previous doses of MenB received since age 14 years
- 1 dose of MenB vaccine required if 1 previous dose of MenB received since age 14 years

NB: Bexsero and Trumenba are not interchangeable

Invalid doses

1st dose administered at ≤28 days of age

Message - Dose given at < minimum age

Minimum interval between any 2 doses not met

Message - Dose given at < minimum interval from previous dose

NB: An invalid dose is to be repeated at the correct schedule point or minimum interval from the previous valid dose if already overdue.

MenB vaccine catch-up for healthy children aged <2 years*

Number of doses given previously	Age at presentation	Age when previous dose of MenB was given			Recommendation Number of further dose(s) required
		1st dose	2nd dose	3rd dose	
No previous doses	<12 months	–	–	–	3
	≥12 months	–	–	–	2
1 previous dose	<12 months	<12 months	–	–	2
	≥12 months	<12 months	–	–	2
	≥12 months	≥12 months	–	–	1
2 previous doses	<12 months	<12 months	<12 months	–	1
	≥12 months	<12 months	<12 months	–	1
	≥12 months	<12 months	≥12 months	–	1
	≥12 months	≥12 months	≥12 months	–	None
3 previous doses	<12 months	<12 months	<12 months	<12 months	1
	≥12 months	<12 months	<12 months	<12 months	1
	≥12 months	<12 months	<12 months	≥12 months	None
	≥12 months	<12 months	≥12 months	≥12 months	None

*No upper age limit for Aboriginal and Torres Strait Islander children

14.2.2 People with specified medical conditions

People who have specified medical conditions listed in the table above

Before splenectomy, follow the catch-up schedule for all children and adolescents. No doses of vaccine should be given within 2 weeks of surgery.

After surgery, and for all other conditions, follow the guidance below:

Valid doses

Minimum age

- Minimum age dose 1 is 29 days
- Minimum accepted age for dose 4 already given is 11 months
- Minimum age dose 4 for future recommendations is 12 months
- Minimum age for booster dose is 4 years

Minimum intervals

- Minimum interval between primary doses is 6 weeks if <6 months of age
- Minimum interval between primary doses is 8 weeks if 6–23 months of age
- Minimum interval between primary doses is 4 weeks if ≥2 years of age for receipt of Bexsero
- For people ≥10 years of age in receipt of Trumenba, minimal interval dose 1- dose 2 is 4 weeks and dose 2- dose 3 is 6 months

- If ≤6 years of age, minimum interval between last primary dose and booster dose is 3 years
- If ≥7 years of age, minimum interval between last primary dose and booster dose is 5 years

Number of doses

- The number of doses required depends on current age and previous doses received and brand, see MenB vaccine (Bexsero) catch-up for people with specified medical conditions below
- For people ≥10 years of age receiving Trumenba, a 3-dose primary schedule is required

NB: Bexsero and Trumenba are not interchangeable for an adolescent schedule

Invalid doses

1st dose administered at ≤28 days of age

Message - Dose given at < minimum age

Minimum interval between any 2 doses not met

Message - Dose given at < minimum interval from previous dose

NB: An invalid dose is to be repeated at the correct schedule point or minimum interval from the previous valid dose if already overdue.

People who have had a haematopoietic stem cell transplant

Valid doses

Minimum intervals

- Minimum interval from transplant - dose 1 is 6 months
- Minimum interval dose 1 - dose 2 is 8 weeks for receipt of Bexsero
- Minimum interval dose 2 - dose 3 is 8 weeks for receipt of Bexsero (only required if vaccination commenced at 6–11 months of age)
- For people ≥10 years of age in receipt of Trumenba, minimal interval dose 1- dose 2 is 4 weeks and dose 2- dose 3 is 6 months
- If ≤6 years of age, minimum interval between last primary dose and booster dose is 3 years
- If ≥7 years of age, minimum interval between last primary dose and booster dose is 5 years
- Minimum interval between first booster dose and second booster dose is 5 years

Number of doses

- For people 6–<12 months of age receiving Bexsero, a 3-dose primary schedule is required
- For people ≥12 months of age receiving Bexsero, a 2-dose primary schedule is required
- For people ≥10 years of age receiving Trumenba, a 3-dose primary schedule is required

NB: Bexsero and Trumenba are not interchangeable for an adolescent schedule

Invalid doses

Dose administered at <6 months from transplant

Message - Dose given at < minimum interval from transplant

Minimum interval between any 2 doses not met

Message - Dose given at < minimum interval from previous dose

NB: An invalid dose is to be repeated at the correct schedule point or minimum interval from the previous valid dose if already overdue.

People who are having/have had a solid organ transplant

Before transplant, follow the catch-up schedule for all children and adolescents. No doses of vaccine should be given within 4 weeks of surgery.

After transplant, follow the guidance below:

Valid doses

Minimum intervals

- Minimum interval from transplant – next scheduled dose is 6 months
- At 6 months follow the catch-up schedule for all children and adolescents

NB: Bexsero and Trumenba are not interchangeable for an adolescent schedule

Invalid doses

Dose administered at <6 months from transplant

Message - Dose given at < minimum interval from transplant

Minimum interval between any 2 doses not met

Message - Dose given at < minimum interval from previous dose

NB: An invalid dose is to be repeated at the correct schedule point or minimum interval from the previous valid dose if already overdue.

MenB vaccine (Bexsero) primary catch-up for people with specified medical conditions

Number of primary doses given previously	Age at presentation	Age when previous dose of MenB was given				Recommendation Number of further primary dose(s) required
		1st dose	2nd dose	3rd dose	4th dose	
No previous doses	<6 months	–	–	–	–	4
	6–<12 months	–	–	–	–	3
	≥12 months	–	–	–	–	2
1 previous dose	<12 months	<6 months	–	–	–	3
	6–<12 months	6–<12 months	–	–	–	2
	≥12 months	<12 months	–	–	–	2
	≥12 months	≥12 months	–	–	–	1
2 previous doses	<12 months	<6 months	<12 months	–	–	2
	<12 months	6–<12 months	6–<12 months	–	–	1
	≥12 months	<6 months	<12 months	–	–	2
	≥12 months	6–<12 months	6–<12 months	–	–	1
	≥12 months	Any age	≥12 months	–	–	1

3 previous doses	<12 months	<12 months	<12 months	<12 months	–	1
	≥12 months	<12 months	<12 months	<12 months	–	1
	≥12 months	<6 months	<12 months	≥12 months	–	1
	≥12 months	6–<12 months	<12 months	≥12 months	–	None
	≥12 months	Any age	≥12 months	≥12 months	–	None

14.3 NIP funding

- All MenB doses for Aboriginal and Torres Strait Islander children born after 1 July 2018, if given at ≤2 years of age.
- People with following specified medical conditions are eligible for all required primary doses to be funded:
 - Functional or anatomical asplenia, including sickle cell disease or other haemoglobinopathies
 - defects in, or deficiency of, complement components, including factor H, factor D or properdin deficiency
 - current or future treatment with eculizumab
- The booster dose of MenB vaccine for people with specified medical conditions is not funded.

15 Pneumococcal conjugate

15.1 Recommended schedule

15.1.1 Non-Aboriginal and Torres Strait Islander children in all states and Aboriginal and Torres Strait Islander children and adolescents in ACT, NSW, TAS & VIC

- 2 primary doses of PCV (pneumococcal conjugate vaccine) at 2 and 4 months of age.
- Booster dose of PCV (pneumococcal conjugate vaccine) at 12 months of age

Note: To avoid confusion, Pneumococcal Conjugate doses should be labelled as Dose 1 of 2, Dose 2 of 2, and Booster 1 of 1.

15.1.2 Aboriginal and Torres Strait Islander children and adolescents in NT, QLD, SA or WA

- 3 primary doses of PCV (pneumococcal conjugate vaccine) at 2, 4 and 6 months of age.
- Booster dose of PCV (pneumococcal conjugate vaccine) at 12 months of age

Note: To avoid confusion, Pneumococcal Conjugate doses should be labelled as Dose 1 of 3, Dose 2 of 3, Dose 3 of 3, and Booster 1 of 1.

15.1.3 People with specified medical conditions

People who have specified medical conditions listed in the table below

- 1 additional dose of PCV (pneumococcal conjugate vaccine) at diagnosis if >6 months OR
- 1 additional dose of PCV (pneumococcal conjugate vaccine) at 6 months of age if diagnosed at <6 months of age
- If a person is diagnosed with a second specified medical condition and they have received all recommended vaccines, they do not repeat these
- For people having a solid organ transplant, where possible, they should receive all scheduled doses at least 4 weeks before transplantation
- For people having an elective splenectomy, where possible, they should receive all scheduled doses at least 2 weeks before surgery

People who have completed cancer therapy

- If not received during treatment, an additional dose of PCV, 6 months after remission or the completion of treatment (whichever is more recent), if previously fully vaccinated before commencing cancer therapy
- If not fully vaccinated prior to cancer therapy, commence catch-up as for healthy children and adolescents (instead of the booster dose), before giving the additional dose.

People who have had a haematopoietic stem cell transplant

- 3 doses of PCV (pneumococcal conjugate vaccine) at 6, 8, 12 months post-transplant

- If any doses from the primary and booster schedule have not been received prior to transplant, these do not need to be given

Specified medical conditions for which an additional dose of PCV is scheduled.

Previous episode of invasive pneumococcal disease	
Functional or anatomical asplenia, including sickle cell disease or other haemoglobinopathies	
Immunocompromising conditions	congenital or acquired immune deficiency
	haematological malignancies
	solid organ transplant
	HIV infection
	immunosuppressive therapy (current or anticipated)
	non-haematological malignancies receiving chemotherapy or radiotherapy (currently or anticipated)
	Defects in, or deficiency of, complement components, including factor H, factor D or properdin deficiency
	Current or future treatment with eculizumab
	Other immunocompromising condition
Proven or presumptive cerebrospinal fluid (CSF) leak	cochlear implants
	intracranial shunts
Chronic respiratory disease	suppurative lung disease, bronchiectasis and cystic fibrosis
	chronic lung disease in preterm infants
	chronic obstructive pulmonary disease (COPD) or chronic emphysema
	severe asthma (defined as requiring frequent hospital visits or the use of multiple medications)
	interstitial and fibrotic lung disease
	other chronic respiratory disease
Chronic renal disease	relapsing or persistent nephrotic syndrome
	Stage 4 chronic kidney disease – eGFR <30 mL/min
	Stage 5 chronic kidney disease (kidney failure) – eGFR <15 mL/min
Cardiac disease	congenital heart disease
	coronary artery disease
	heart failure
	long-term aspirin therapy in children aged 6 months to 10 years
	other cardiac disease
Pre-term infant or low-birth weight baby	children born less than 28 weeks gestation

	low-birth weight baby
Trisomy 21	
Chronic liver disease	chronic hepatitis
	cirrhosis
	biliary atresia
	other chronic liver disease
Diabetes	
Smoking (current or in the immediate past)	
Harmful use of alcohol (consuming on average ≥ 60 g of alcohol/day for males and ≥ 40 g of alcohol/day for females)	

15.2 Catch up dose parameters

15.2.1 Non-Aboriginal and Torres Strait Islander children in all states and Aboriginal and Torres Strait Islander children and adolescents in ACT, NSW, TAS & VIC

Valid doses

Minimum age

- Minimum age dose 1 is 29 days
- Minimum accepted age for dose 3 already given is 11 months for children born on or after 1/7/2017.
- For children born on or before 30/6/2017, dose 3 already given at any age is accepted provided the minimum age for dose 1 and minimum intervals of at least 4 weeks between any doses given at <12 months and 8 weeks between any doses given at ≥ 12 months have been met.
- Minimum age dose 3 for future recommendations is 12 months for all children

Maximum age

- Maximum age is 4 years (immediately prior to the 5th birthday)

Minimum intervals

- Minimum interval between primary doses at age <12 months is 4 weeks (calculated from the age at which the previous dose was given – ie <12 months)
- Minimum interval between any 2 doses given at ≥ 12 months is 8 weeks (calculated from the age at which the previous dose was given – ie ≥ 12 months)
- Minimum interval between last primary dose and booster dose is 8 weeks

Number of doses

The number of doses required depends on current age and previous doses received, see *PCV catch-up for non-Aboriginal and Torres Strait Islander children aged < 5 years in all states and Aboriginal and Torres Strait Islander children aged <5 years in ACT, NSW, TAS & VIC*

Invalid doses

1st dose administered at ≤ 28 days of age

3rd dose administered at < 11 months age for children born 1/7/2017 onwards

Message - Dose given at $<$ minimum age

3rd dose administered at 11 - < 12 months age for children born 1/7/2017 onwards

Message – No message to be displayed.

NB: This dose is not repeated at ≥ 12 months of age provided the minimum interval from the last primary dose has been met.

Minimum interval between any 2 doses not met

Message - Dose given at $<$ minimum interval from previous dose

NB: An invalid dose is to be repeated at the correct schedule point or minimum interval from the previous valid dose if already overdue.

PCV catch-up for non-Aboriginal and Torres Strait Islander children aged < 5 years in all states and Aboriginal and Torres Strait Islander children aged < 5 years in ACT, NSW, TAS & VIC.

Number of doses given previously	Age at presentation	Age when previous dose of PCV was given			Recommendation Number of further dose(s) required
		1st dose	2nd dose	3rd dose	
No previous doses	< 12 months	–	–	–	3
	12–59 months	–	–	–	1
1 previous dose	< 12 months	< 12 months	–	–	2
	12–59 months	< 12 months	–	–	1
		≥ 12 months	–	–	None
2 previous doses	< 12 months	< 12 months	< 12 months	–	1
	12–59 months	< 12 months	< 12 months	–	1
			≥ 12 months	–	None
3 previous doses	< 12 months	< 12 months	< 12 months	< 12 months	1
	12–59 months	< 12 months	< 12 months	< 12 months	None
	12–59 months	< 12 months	< 12 months	12–59 months	None
	12–59 months	< 12 months	12–59 months	12–59 months	None
	12–59 months	12–59 months	12–59 months	12–59 months	None

15.2.2 Aboriginal and Torres Strait Islander children and adolescents in NT, QLD, SA or WA

Valid doses

Minimum age

- Minimum age dose 1 is 29 days
- The dose 3 minimum age rule does not apply to this group
- Minimum accepted age dose 4 for a dose already given is 11 months

- Minimum accepted age dose 4 for future recommendations is 12 months

Maximum age

- Maximum age is 4 years (immediately prior to the 5th birthday)

Minimum intervals

- Minimum interval between primary doses at age <12 months is 4 weeks (calculated from the age at which the previous dose was given – ie <12 months)
- Minimum interval between any 2 doses given at ≥12 months is 8 weeks (calculated from the age at which the previous dose was given – ie ≥12 months)
- Minimum interval between last primary dose and booster dose is 8 weeks
- Minimum interval between previous dose of 23vPPV and a dose of PCV is 12 months

Number of doses

The number of doses required depends on current age and previous doses received, see *PCV catch-up for Aboriginal and Torres Strait Islander children living in NT, QLD, SA or WA aged <5 years and children with specified medical conditions below*

Invalid doses

1st dose administered at ≤28 days age

4th dose administered at <11 months age

Message - Dose given at < minimum age

4th dose administered at 11 - <12 months age

Message – No message to be displayed.

NB: This dose is not repeated at ≥ 12 months of age provided the minimum interval from the last primary dose has been met.

Minimum interval between any 2 doses not met

Message - Dose given at < minimum interval from previous dose

NB: An invalid dose is to be repeated at the correct schedule point or minimum interval from the previous valid dose if already overdue.

PCV catch-up for Aboriginal and Torres Strait Islander children living in NT, QLD, SA or WA aged <5 years and children with specified medical conditions

Number of doses given previously	Age at presentation	Age when previous dose of PCV was given			Recommendation Number of further dose(s) required
		1st dose	2nd dose	3rd dose	
No previous doses	<12 months	–	–	–	4
	12–59 months	–	–	–	2
1 previous dose	<12 months	Any age	–	–	3
	12–59 months	<12 months	–	–	2
		≥12 months	–	–	1
2 previous doses	<12 months	Any age	Any age	–	2
	12–59 months	<12 months	<12 months	–	2
				≥12 months	–

3 previous doses	<12 months	≥12 months	≥12 months	–	None
	12–59 months	Any age	Any age	Any age	1
	12–59 months	<12 months	<12 months	Any age	1
	12–59 months	<12 months	<12 months	12–59 months	1
	12–59 months	<12 months	12–59 months	12–59 months	None

15.2.3 People with specified medical conditions

People who have specified medical conditions listed above

Before solid organ transplant, follow the catch-up schedule for all children and adolescents. No doses of vaccine should be given within 4 weeks of surgery.

Before splenectomy, follow the catch-up schedule for all children and adolescents. No doses of vaccine should be given within 2 weeks of surgery.

After surgery, and for all other conditions, follow the guidance below:

Valid doses

Minimum age

The dose 3 minimum age rule does not apply to this group

Maximum age

Maximum age of 4 years (immediately prior to the 5th birthday) does NOT apply for this cohort. Instead it should be 19 years (immediately prior to the 20th birthday).

Minimum intervals

- Minimum interval from transplant – next scheduled dose is 6 months
- Minimum interval is 8 weeks after any previous doses of PCV
- Minimum interval between previous dose of 23vPPV and a dose of PCV is 12 months

Number of doses

- The number of doses required depends on current age and previous doses received, see *PCV catch-up for Aboriginal and Torres Strait Islander children living in NT, QLD, SA or WA aged <5 years and children with specified medical conditions*
- For people ≥5 years of age a single dose of PCV is required

Invalid doses

Dose administered at <6 months from transplant

Message - Dose given at < minimum interval from transplant

Minimum interval between any 2 doses not met

Message - Dose given at < minimum interval from previous dose

NB: An invalid dose is to be repeated at the correct schedule point or minimum interval from the previous valid dose if already overdue.

People who have had a haematopoietic stem cell transplant

Valid doses

Minimum intervals

- Minimum interval from transplant - dose 1 is 6 months
- Minimum interval dose 1 - dose 2 is 2 months
- Minimum interval dose 2 - dose 3 is 16 weeks

Maximum age

- Maximum age of 4 years (immediately prior to the 5th birthday) does NOT apply for this cohort.

Invalid doses

Booster dose administered at <6 months from transplant

Message - Dose given at < minimum interval from transplant

Minimum interval between any 2 doses not met

Message - Dose given at < minimum interval from previous dose

NB: An invalid dose is to be repeated at the correct schedule point or minimum interval from the previous valid dose if already overdue.

15.3 NIP funding

All scheduled childhood doses are funded using 13vPCV for non-Aboriginal and Torres Strait Islander children and Aboriginal and Torres Strait Islander children.

The following people with specified medical conditions are eligible for additional funded doses of 13vPCV:

- Previous episode of invasive pneumococcal disease
- Functional or anatomical asplenia, including sickle cell disease or other haemoglobinopathies
- Congenital or acquired immune deficiency
- Haematological malignancies
- Solid organ transplant
- Haematopoietic stem cell transplant
- HIV infection
- Cochlear implants
- Intracranial shunts
- Suppurative lung disease, bronchiectasis and cystic fibrosis
- Chronic lung disease in preterm infants
- Relapsing or persistent nephrotic syndrome
- Stage 5 chronic kidney disease (kidney failure) – eGFR <15 mL/min

Children <5 years of age with the following specified medical conditions are eligible for an additional funded dose of 13vPCV:

- Congenital heart disease
- Coronary artery disease

- Heart failure
- Children born less than 28 weeks gestation
- Trisomy 21

15vPCV and 20vPCV are not funded on the NIP.

16 Pneumococcal polysaccharide

16.1 Recommended schedule

16.1.1 Non-Aboriginal and Torres Strait Islander children in all states and Aboriginal and Torres Strait Islander children in ACT, NSW, TAS & VIC

No additional recommendations

16.1.2 Aboriginal and Torres Strait Islander children and adolescents in NT, QLD, SA or WA

- 1 dose of 23vPPV (pneumococcal polysaccharide vaccine) 12 months after 13vPCV (2–12 months later is acceptable) or at 4 years of age whichever is later
- a 2nd dose of 23vPPV (pneumococcal polysaccharide vaccine) at least 5 years after the first dose of 23vPPV

Note: To avoid confusion, Pneumococcal Polysaccharide doses should be labelled as Dose 1 and Dose 2.

16.1.3 People with specified medical conditions

People who have specified medical conditions listed in the table below or who have had a haematopoietic stem cell transplant

- 1 dose of 23vPPV (pneumococcal polysaccharide vaccine) 12 months after 13vPCV (2–12 months later is acceptable) or at 4 years of age whichever is later
- a 2nd dose of 23vPPV (pneumococcal polysaccharide vaccine) at least 5 years after the first dose of 23vPPV
- If a person is diagnosed with a second specified medical condition and they have received all recommended vaccines, they do not repeat these

People who have completed cancer therapy

- If not received during treatment, the schedule of 23vPPV described above for people with a specified medical condition should be completed, commencing 6 months after remission or the completion of treatment (whichever is more recent), if previously fully vaccinated with 13vPCV before commencing cancer therapy.
- If not fully vaccinated prior to cancer therapy, commence catch-up as for healthy children and adolescents, before giving additional doses.

Specified medical conditions for which doses of 23vPPV are scheduled

Haematopoietic Stem Cell Transplant

Previous episode of invasive pneumococcal disease

Functional or anatomical asplenia, including sickle cell disease or other haemoglobinopathies

Immunocompromising conditions	congenital or acquired immune deficiency
	haematological malignancies
	solid organ transplant
	HIV infection
	immunosuppressive therapy (current or anticipated)
	non-haematological malignancies receiving chemotherapy or radiotherapy (currently or anticipated)
	Defects in, or deficiency of, complement components, including factor H, factor D or properdin deficiency
	Current or future treatment with eculizumab
	Other immunocompromising condition
Proven or presumptive cerebrospinal fluid (CSF) leak	cochlear implants
	intracranial shunts
Chronic respiratory disease	suppurative lung disease, bronchiectasis and cystic fibrosis
	chronic lung disease in preterm infants
	chronic obstructive pulmonary disease (COPD) or chronic emphysema
	severe asthma (defined as requiring frequent hospital visits or the use of multiple medications)
	interstitial and fibrotic lung disease
	other chronic respiratory disease
Chronic renal disease	relapsing or persistent nephrotic syndrome
	Stage 4 kidney disease – eGFR <30 mL/min
	Stage 5 kidney disease (kidney failure) – eGFR <15 mL/min
Cardiac disease	congenital heart disease
	coronary artery disease
	heart failure
	long-term aspirin therapy in children aged 6 months to 10 years
	other cardiac disease
Pre-term infant	children born less than 28 weeks gestation
Trisomy 21	
Chronic liver disease	chronic hepatitis
	Cirrhosis
	biliary atresia
	other chronic liver disease
Diabetes	
Smoking (current or in the immediate past)	

Harmful use of alcohol (consuming on average ≥ 60 g of alcohol/day for males and ≥ 40 g of alcohol/day for females)

16.2 Catch up dose parameters

16.2.1 Aboriginal and Torres Strait Islander children and adolescents in NT, QLD, SA or WA

Valid doses

Minimum age

- Minimum age dose 1 is 18 months

Minimum intervals

- Minimum interval between dose of 13vPCV and 23vPPV where already given is 2 months
- Minimum interval for future dose 1 of 23vPPV after dose of 13vPCV is 12 months
- Minimum interval between 2 doses of 23vPPV is 5 years

Invalid doses

1st dose administered at <18 months of age

Message - Dose given at < minimum age

Minimum interval between any 2 doses not met

Message - Dose given at < minimum interval from previous dose

16.2.2 People with specified medical conditions

People who have specified medical conditions listed in the table above or who have had a haematopoietic stem cell transplant

Valid doses

Minimum age

- Minimum age dose 1 is 18 months

Minimum intervals

- Minimum interval between dose of 13vPCV and 23vPPV where already given is 2 months
- Minimum interval for future dose 1 of 23vPPV after dose of 13vPCV is 12 months
- Minimum interval between 2 doses of 23vPPV is 5 years

Invalid doses

1st dose administered at <18 months of age

Message - Dose given at < minimum age

Minimum interval between any 2 doses not met

Message - Dose given at < minimum interval from previous dose

16.3 NIP funding

Two doses of 23vPPV are funded for Aboriginal and Torres Strait Islander children in NT, QLD, SA or WA and the following people with specified medical conditions:

- Previous episode of invasive pneumococcal disease
- Functional or anatomical asplenia, including sickle cell disease or other haemoglobinopathies
- Congenital or acquired immune deficiency
- Haematological malignancies
- Solid organ transplant
- Haematopoietic stem cell transplant
- HIV infection
- Cochlear implants
- Intracranial shunts
- Suppurative lung disease, bronchiectasis and cystic fibrosis
- Chronic lung disease in preterm infants
- Relapsing or persistent nephrotic syndrome
- Stage 5 kidney disease (kidney failure) – eGFR <15 mL/min

Two doses of 23vPPV are funded for children <5 years of age with the following specified medical conditions :

- Congenital heart disease
- Coronary artery disease
- Heart failure
- Children born less than 28 weeks gestation
- Trisomy 21

17 Rotavirus

17.1 Recommended schedule

17.1.1 All children

- 2 primary doses of rotavirus vaccine at 2 and 4 months of age.

17.1.2 Aboriginal and Torres Strait Islander children

No additional recommendations

17.1.3 Children with specified medical conditions

People who are severely immunocompromised

- Vaccination is contraindicated for children with congenital or acquired immune deficiency, on immunosuppressive therapy (current or anticipated) or HIV infection with an age-specific CD4+ count <15% of total lymphocytes

17.1.4 Catch up dose parameters

Valid doses

Minimum age

- Minimum age dose 1 is 29 days

Maximum age

- Maximum age dose 1 is 14 weeks and 6 days (<15 weeks age)
- Maximum age dose 2 is 24 weeks and 6 days (<25 weeks age)
- If dose 1 is not administered by 14 weeks and 6 days of age, NO doses are to be given.
- If dose 1 has already been given at > the recommended age limit dose 2 is recommended as per the schedule provided the minimum dose intervals and upper age limits for subsequent doses can be met.

Minimum intervals

- Minimum interval between dose 1 and dose 2 is 4 weeks

Invalid doses

1st dose administered at ≤ 28 days of age

Message - Dose given at < minimum age

Minimum interval between any 2 doses not met

Message - Dose given at < minimum interval from previous dose

NB: An invalid dose is to be repeated at the correct schedule point or minimum interval from the previous invalid dose if already overdue, as long as maximum age limits are not exceeded

18 Varicella

NB: Please read Varicella rules in conjunction with MMR rules.

18.1 Recommended schedule

18.1.1 All children and adolescents

- Dose 1 of varicella containing vaccine (delivered as MMRV) at 18 months of age, provided a valid dose of MMR was delivered in the past.
- Dose 2 of varicella vaccine (delivered as varicella only vaccine) at least 4 weeks later

18.1.2 Aboriginal and Torres Strait Islander children and adolescents

No additional recommendations

18.1.3 People with specified medical conditions

People who have completed cancer therapy

- 2 booster doses of varicella vaccine, at least 4 weeks apart, after 6 months in remission or the completion of treatment(whichever is most recent), if seronegative
- These doses are given instead of those recommended for all children, not in addition to them.

People who have had a haematopoietic stem cell transplant

- 2 doses of varicella vaccine, at least 4 weeks apart, at 24 months post-transplant, if seronegative
- These doses are given instead of those recommended for all children, not in addition to them.

People who are having a solid organ transplant

- Where possible, children and adolescents should receive all routine scheduled doses at least 4 weeks before transplantation
- Vaccination is contraindicated after transplantation

People who are severely immunocompromised

- Vaccination is contraindicated for children and adolescents with the following conditions: congenital or acquired immune deficiency, haematological malignancies, receiving chemotherapy or radiotherapy (currently or anticipated), HIV infection with an age-specific CD4+ count <15% of total lymphocytes, immunosuppressive therapy (current or anticipated)

18.2 Catch up dose parameters

18.2.1 All children and adolescents

Valid doses

Minimum age

- Minimum age dose 1 for future recommendations is 18 months

- Minimum accepted age for dose already given is 12 months

Minimum intervals

- Minimum interval between any MMRV or Varicella only vaccine is 4 weeks
- Minimum interval between any MMRV or Varicella only vaccine and another live vaccine is 4 weeks

MMRV

- MMRV is recommended as the first dose of MMR containing vaccine in any child ≥ 4 years of age who also requires protection against varicella
- MMRV should not be used for any dose in people ≥ 14 years of age

Invalid doses

1st dose administered at < 12 months of age.

Message - Dose given at $<$ minimum age

Minimum interval between any dose of MMR and / or Varicella containing vaccine not met

Message - Dose given at $<$ minimum interval from previous dose

NB: An invalid dose is to be repeated at the correct schedule point or minimum interval from the previous invalid dose if already overdue.

18.2.2 People with specified medical conditions

People who have completed cancer therapy

Valid doses

Minimum intervals

- Minimum interval from remission/end of treatment - booster dose is 6 months
- Minimum interval between any MMRV or Varicella only vaccine is 4 weeks

Invalid doses

Booster dose administered at < 6 months from remission or end of treatment

Message - Dose given at $<$ minimum interval from remission or end of treatment

Minimum interval between any dose of MMR and / or Varicella containing vaccine not met

Message - Dose given at $<$ minimum interval from previous dose

NB: An invalid dose is to be repeated at the correct schedule point or minimum interval from the previous invalid dose if already overdue.

Children who have had a haematopoietic stem cell transplant

Valid doses

Minimum intervals

- Minimum interval from transplant - dose 1 is 24 months
- Minimum interval from dose 1 - dose 2 is 4 weeks

Invalid doses

Booster dose administered at <24 months from transplant

Message - Dose given at < minimum interval from transplant

Minimum interval between any dose of MMR and / or Varicella containing vaccine not met

Message - Dose given at < minimum interval from previous dose

NB: An invalid dose is to be repeated at the correct schedule point or minimum interval from the previous invalid dose if already overdue.

People who are having a solid organ transplant

Prior to surgery, follow the catch-up schedule for all children and adolescents. No doses of vaccine should be given after surgery.

18.3 NIP funding

Anyone younger than 14 years of age, who have never been immunised (i.e. have not received Varicella dose/s), is eligible for 1 funded dose.

Anyone between 14 and 20 years of age, who have never been immunised (i.e. have not received Varicella dose/s), is eligible for 2 funded doses.

Immunisationhandbook.health.gov.au

All information in this publication is correct as at April 2024

